Severe myelosuppression following alopecia shortly after the initiation of 6-mercaptopurine in a patient with Crohn's disease

7Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

A 15-year-old, woman, Crohn's disease patient, who carried the TPMT *3C heterozygous mutant, complained of alopecia 3 days after starting 6-mercaptopurine (6-MP) and then developed severe myelosuppression 6 weeks after starting 6-MP. The alopecia involved scalp hair only (body hair preserved) and was dominant in the temporal region. Following these side effects, transient remission of Crohn's disease occurred. Myelosuppression due to 6-MP is a rare but life-threatening side effect that is difficult to predict despite continuous monitoring of complete blood cell counts. In the present case, 6-MP-induced alopecia preceded myelosuppression and progressed rapidly as the myelosuppression worsened. © 2009 The Japanese Society of Internal Medicine.

Cite

CITATION STYLE

APA

Ugajin, T., Miyatani, H., Demitsu, T., Iwaki, T., Ushimaru, S., Nakashima, Y., & Yoshida, Y. (2009). Severe myelosuppression following alopecia shortly after the initiation of 6-mercaptopurine in a patient with Crohn’s disease. Internal Medicine, 48(9), 693–695. https://doi.org/10.2169/internalmedicine.48.1736

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free